Incorporating MRD Detection & Cell-Free DNA into Clinical Trials: A Comprehensive Overview
Time: 12:45 pm
day: Day Two
Details:
- Advanced patient selection strategies in clinical trials: Leveraging cell-free DNA (cfDNA) for precise patient stratification and selection to enhance trial outcomes and personalized medicine
- Innovative detection of minimal residual disease (MRD) and patient surveillance: Utilizing cfDNA as a cutting-edge tool for monitoring MRD and conducting ongoing patient surveillance, improving early detection and intervention
- Technological innovation: Understanding the impact of novel technologies on MRD detection and ctDNA analysis
